NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









EdiGene

EdiGene

Private
BeijingHealthcare & Life Scienceshttps://edigene.com/

Last Round

Series B

Extension

Apr 21, 2021

Total Funding Raised

$160M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

EdiGene is a biotechnology company that develops genome editing technologies to accelerate drug discovery and create novel therapeutics for genetic diseases and cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene editingRNA editingCRISPRcell therapygene therapygenetic medicinegenomic medicinebiotechhematopoietic stem cell therapyin vivo therapyex vivo therapydrug discoverybase editingclinical stage biotechtherapeutic platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EdiGene Comparables

Compare EdiGene with similar companies based on industry and business-model similarity.

EdiGene comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BRL Medicine Inc.
87%
Shanghai Bendao Gene Technology
84%
AIRNA
80%

EdiGene Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionApr 21, 2021
Series BOct 13, 2020
Series A ExtensionSep 16, 2019
Series A ExtensionFeb 4, 2019
VC RoundAug 24, 2018

EdiGene Investors

Notable investors and investment history

EdiGene investors
InvestorRounds
Alwin CapitalSeries B Extension, Series B
BioTrack CapitalSeries B Extension
BGI Co-WinVC Round
Loyal Valley CapitalSeries B Extension
IDG CapitalVC Round, Series B Extension, Series B, Series A Extension, Series A
Sincere CapitalVC Round, Series B
WI Harper GroupSeries A, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 17, 2026

    Monthly visitors increased 144% MoM.

  • Apr 15, 2026

    Monthly visitors grew 120% MoM.

EdiGene Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

EdiGene Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about EdiGene's valuation, stock price, and market status.

Firmographic Details

HeadquartersBeijing
Employee Range46
Year Founded2015
Last FundingApr 21, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.